Maze Therapeutics reports positive Phase 1 results for MZE782

Maze Therapeutics has announced positive results from the Phase 1 trial of MZE782, an oral SLC6A19 inhibitor designed to treat phenylketonuria (PKU) and chronic kidney disease (CKD). The randomized, double-blind, placebo-controlled study involved 112 healthy adult volunteers and evaluated single and…